PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Positive gross profit growth while AGEN is negative. John Neff would see a clear operational edge over the competitor.
-29.39%
Negative EBIT growth while AGEN is at 32.18%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-29.39%
Negative operating income growth while AGEN is at 8.18%. Joel Greenblatt would press for urgent turnaround measures.
-30.95%
Negative net income growth while AGEN stands at 14.23%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-22.58%
Negative EPS growth while AGEN is at 17.11%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.58%
Negative diluted EPS growth while AGEN is at 17.11%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
7.95%
Share count expansion well above AGEN's 3.41%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.95%
Diluted share count expanding well above AGEN's 3.41%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-8.11%
Negative OCF growth while AGEN is at 0.03%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-7.95%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AGEN stands at 15.94%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.14%
10Y OCF/share CAGR above 1.5x AGEN's 40.24%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
75.06%
5Y OCF/share CAGR 1.25-1.5x AGEN's 65.82%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
-16.88%
Negative 3Y OCF/share CAGR while AGEN stands at 63.63%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-109.23%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
62.10%
5Y net income/share CAGR similar to AGEN's 66.49%. Walter Schloss might see both on parallel mid-term trajectories.
-51.96%
Negative 3Y CAGR while AGEN is 66.28%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-71.08%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-53.15%
Negative 5Y equity/share growth while AGEN is at 50.95%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-63.40%
Negative 3Y equity/share growth while AGEN is at 48.33%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Asset growth well under 50% of AGEN's 13.98%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-7.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-6.71%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
37.48%
We increase R&D while AGEN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
21.30%
SG&A growth well above AGEN's 24.74%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.